Previous Article | Next Article ![]()
Molecular and Cellular Biology, October 2001, p. 6537-6548, Vol. 21, No. 19
Department of Biochemistry, University of
Alberta, Edmonton, Alberta T6G 2H7, Canada
Received 2 April 2001/Returned for modification 10 May
2001/Accepted 9 July 2001
We describe the creation of a pluripotent ubiquitin-conjugating
enzyme (E2) generated through a single amino acid substitution within
the catalytic domain of RAD6 (UBC2). This RAD6 derivative carries out
the stress-related function of UBC4 and the cell cycle function of
CDC34 while maintaining its own DNA repair function. Furthermore, it
carries out CDC34's function in the absence of the CDC34
carboxy-terminal extension. By using sequence and structural comparisons, the residues that define the unique functions of these
three E2s were found on the E2 catalytic face partitioned to either
side by a conserved divide. One of these patches corresponds to a
binding site for both HECT and RING domain proteins, suggesting that a
single substitution in the catalytic domain of RAD6 confers upon it the
ability to interact with multiple ubiquitin protein ligases (E3s).
Other amino acid substitutions made within the catalytic domain of RAD6
either caused loss of its DNA repair function or modified its ability
to carry out multiple E2 functions. These observations suggest that
while HECT and RING domain binding may generally be localized to a
specific patch on the E2 surface, other regions of the functional E2
face also play a role in specificity. Finally, these data also indicate
that RAD6 uses a different functional region than either UBC4 or CDC34,
allowing it to acquire the functions of these E2s while
maintaining its own. The pluripotent RAD6 derivative, coupled with
sequence, structural, and phylogenetic data, suggests that E2s have
diverged from a common multifunctional progenitor.
Ubiquitin-conjugating enzymes (E2s)
comprise a class of eukaryotic enzymes that function at an intermediate
step in the reaction pathway leading to protein ubiquitination.
Initially, E2s accept ubiquitin from the active-site cysteine of a
ubiquitin-activating enzyme (E1) to their own active-site cysteine via
a transthiolation reaction. Subsequently, thiol ester-linked ubiquitin
is donated by E2s in one of two possible ways. E2s may transfer
ubiquitin directly to a lysine side chain found either on a protein
substrate or on a ubiquitin moiety in a growing multiubiquitin chain
through the formation of an isopeptide bond. Alternatively, E2s
transfer ubiquitin to a cysteine of a ubiquitin protein ligase (E3)
through a second transthiolation reaction. In the former case, an E3
functions to assist the E2 in the recognition of a protein substrate,
while in the latter case, it is believed that the E3 directly links ubiquitin to either the protein substrate or a growing multiubiquitin chain. Assembly of a multiubiquitin chain on a protein substrate by
either an E2 or an E3 targets the protein for degradation by the 26S
proteosome (35, 39, 43).
E2s have been shown to consist of a conserved catalytic domain that
contains the active-site cysteine. This conservation is observed in
both sequence and structural comparisons of E2s. For example, the 11 E2s and two ubiquitin-like conjugating enzymes (UBC9 and UBC12) from
the yeast Saccharomyces cerevisiae exhibit between 20 and
92% identity. Superimposition of the six solved E2 crystal structures
also makes it apparent that the three-dimensional folding of different
E2s shows little variation (3-5, 16, 54, 58). It is
thought that the requirement of E2s to interact with E1 and ubiquitin
(or their cognates) during E2-ubiquitin thiol ester formation placed
considerable evolutionary constraints on the E2 structure, resulting in
the observed conservation (4, 50).
Although E2s have a function in common in ubiquitin thiol ester
formation, they have also been shown to function within a wide range of
cellular pathways resulting in the ubiquitination of protein substrates
particular to those pathways. This requires that downstream of
E2-ubiquitin thiol ester formation, an E2 must interact with proteins
that are specific to that pathway, such as an E3 or a target, through
unique points of contact other than those employed with ubiquitin and E1.
To acquire these individual functional characteristics, E2s have
exploited tolerable levels of structural variation. One source of
structural variety comes in the form of carboxy- and amino-terminal extensions to the conserved catalytic domain, the type II, III, and IV
E2s (15). In addition, loop structures can result from amino acid insertions within the conserved catalytic domain. These additions to the catalytic domain have been reported to contribute to
the unique functional characteristics of several E2s. For example, CDC34 (UBC3) from S. cerevisiae is required for the
G1 to S phase transition of the cell cycle
(10) and is responsible for the degradation of several
cell cycle-related proteins (7). CDC34 possesses both a
carboxy-terminal extension and an insertion near its active-site
cysteine, both of which play a role in its cell cycle function
(26, 31, 50). Furthermore, the carboxy-terminal extension
has been shown to help mediate the interaction between CDC34 and its
E3, namely, the SCF complex (32).
The type I E2s (15), however, are capable of performing
their unique cellular functions without the requirement of extensions or insertions. In these cases, protein interactions unique to an E2
must be determined solely by the distribution of specific amino acid
side chains on the conserved catalytic domain surface. In the present
work, we demonstrate that a single amino acid replacement within an E2
catalytic domain results in the acquisition of two other E2 functions
in addition to its own. These results shed light on the nature of E2-E3
interactions and suggest that E2s may have evolved from a pluripotent progenitor.
Plasmids and yeast strains.
The S. cerevisiae
high-copy-number, TRP1-based E2 expression plasmids used in
growth and UV sensitivity studies are identical to YEP96
(8), except that the rad6
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.19.6537-6548.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Creation of a Pluripotent
Ubiquitin-Conjugating Enzyme
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
C,
ubc1
C, and UBC4 coding sequences
replace the ubiquitin coding sequence. The specific codon changes and
the corresponding residue changes for each of these E2 sequences are
listed in Table 1. Group A (plasmids 1 to
3) are the parental E2 constructs that were used as positive controls
throughout this study. rad6
C encodes a
truncated version of RAD6 that contains the functionally active
catalytic domain (residues 1 to 153) but lacks the C-terminal acidic
tail (residues 154 to 172). Additional codon changes within
rad6
C reflect the creation of new restriction
sites within the coding sequence to facilitate subsequent gene
manipulation. Changes at codon positions 2 and 3, 51 and 52, 98 and 99, and 153 create the restriction sites SacI, KasI,
SmaI, and EcoRV, respectively. Changes at codons 2, 51, 98, and 99 have no effect on the polypeptide sequence, whereas
changes at codons 3, 52, and 153 result in conservative amino acid
replacements (Table 1). The rad6
C plasmid
fully complements the UV sensitivity of a rad6
-null
strain in either the low-copy-number or the high-copy-number form.
TABLE 1.
Yeast E2 expression plasmidsa
C introduced a SacI
restriction site without alteration of the UBC4 polypeptide sequence,
whereas an R-to-S substitution is introduced at codon 3 of
ubc1
C (Table 1, plasmids 2 and 3). In
ubc1
C, the codons specifying its 64-residue
C-terminal tail have also been deleted. Both low- and high-copy-number
ubc1
C and UBC4 plasmids restore
UBC4 function to a ubc4
ubc5
-null strain.
All subsequent substitutions (plasmids 4 to 29) were made within the
context of the three parental plasmids described above. Plasmids in
group B each have substitutions that resulted in the transposition of
selected amino acid residues from one E2 to their corresponding
positions in another E2. Plasmids 4 to 16 encode substitutions in
RAD6
C that replace selected residues with their UBC4 counterparts,
whereas substitutions in plasmid 18 replace selected residues within
UBC4 with their RAD6 counterparts. Plasmid 17 was constructed to test
whether the previously reported role for residues R6, R7, and R8 of
RAD6 in DNA repair could be ascribed to residue R8 (33).
The residue positions chosen for replacement were selected because they
are strongly conserved within either the RAD6 or the UBC4 E2 family but
exhibit poor conservation between families. E2 derivatives expressed
from plasmids in group C (19 to 23) each contain a
contiguous stretch of residues that have been transposed from one E2
into the corresponding position of the other E2. Plasmids listed in
group D (24 to 29) encode amino acid substitutions in
ubc1
C whose phenotypic behavior was used in the construction of Fig.
4 and 5. All of the substitutions described in Table 1 were verified by
DNA sequencing.
Low-copy-number TRP1 S. cerevisiae expression plasmids
(encoding a selected set of rad6
C, ubc1
C, or UBC4 derivatives)
were constructed by positioning the BamHI/ClaI
fragment (containing the CUP1 promoter, the E2 coding
sequence, and the CYC1 terminator) of the plasmids described
above between the BamHI and ClaI sites of
CEN/ARS plasmid pRS314 (49).
High-copy-number, TRP1-based plasmids encoding CDC34 or the
C-terminal truncation of cdc34
170 have been
previously described (50).
The pET3a-based rad6
C and
ubc1
C plasmids used for the expression and
purification of recombinant protein from Escherichia coli
are identical in sequence to the pET3a-ubc1
C
plasmid described elsewhere (12), except for the coding
sequences for each of the rad6
C and ubc1
C derivatives described
in Table 2.
pET3a-rad6
C and its derivatives also contain
the following Arg codon substitutions, which were found to dramatically
increase their levels of expression: Arg-6, -7, and -11 (AGA to CGA)
and Arg-8 (AGG to CGG). Details pertaining to the construction of all
plasmids are available on request.
|
ubc5
-null strain MHY508 (obtained
from M. Hochstrasser). MHY508 (2) has the genotype
MAT
his3
200 leu2-3,112 ura3-52
lys2-801 trp1-1 ubc4
1::HIS3
ubc5
1::LEU2. For UV sensitivity studies,
plasmids were introduced into rad6
-null strain KMY20
(obtained from K. Madura). KMY20 has the genotype MATa
ade2-1 his3-832 trp1-289 ura3-52
rad6
::URA3.
To test for 5-fluoroorotic acid (FOA) sensitivity, plasmids were
introduced into cdc34
-null strain YES71 (MAT
ura3-52 trp1-63 leu2
1 his3
cdc34-2
::HIS3). Viability of YES71 is
maintained by a high-copy-number URA3 expression plasmid
that encodes CDC34.
Phenotype analysis.
For growth studies, strains MHY508 and
KMY20 containing TRP1 vectors were grown in fully
supplemented SD liquid medium lacking tryptophan (48) to
exponential growth phase. Cells (105) from each
culture were then plated onto fully supplemented SD plates (lacking
tryptophan) and grown at 30°C. Growth was scored on the basis of
colony size. Colonies were given designations of + to ++++++ based on
their sizes relative to colonies produced by cells expressing either
rad6
C (+) or UBC4 (++++++). For stress sensitivity experiments,
MHY508 strains were grown at 30°C on plates in the presence or
absence of canavanine sulfate (1.5 µg/ml) or at the temperatures
indicated. Colonies were counted after 7 days. For UV sensitivity
experiments, plates containing KMY20 strains were irradiated with 72 J of short-wavelength UV light (254 nm) per
m2. Plasmid rescue of the
cdc34
-null defect associated with YES71 was assessed by
determining the persistence of cell viability upon loss of the
URA3-CDC34 maintenance plasmid in the presence of FOA. Cells
were grown to early exponential phase in fully supplemented SD liquid
medium lacking uracil and tryptophan. Cells (106)
were then spread onto fully supplemented SD plates containing FOA (1 mg/ml) and then incubated at 25°C for 5 days. Colony formation indicated loss of the URA3-CDC34 maintenance plasmid and
complementation of the cdc34
-null defect by the E2 gene
of the TRP1-based plasmid.
Protein expression and purification.
Expression of protein
from pET3a plasmids, cell harvesting, and lysis were performed as
previously described for CDC34 (15). For the purification
of rad6
C and its derivatives, clarified supernatants were passed
over a MonoQ HR 5/10 ion-exchange column (Pharmacia) equilibrated with
50 mM Tris-HCl (pH 7.5)-1 mM EDTA-1 mM dithiothreitol (DTT) and the
proteins were eluted with an NaCl gradient of 0 to 1 M. rad6
C eluted
at approximately 240 mM NaCl. The Mono Q fractions were concentrated by
Centricon (Amicon) filtration and then loaded onto a Superdex 75 HR
10/30 size exclusion column (Pharmacia) equilibrated with 50 mM HEPES
(pH 7.5)-150 mM NaCl-1 mM EDTA-1 mM DTT. Peak fractions were
collected, pooled, and concentrated to 500 µl. Glycerol was added to
a final concentration of 5%, and the protein samples were stored at
80°C. Expression of 35S-radiolabeled
ubiquitin and subsequent cell lysis were carried out as previously
described for 35S-radiolabeled CDC34
(38). For the purification of ubc1
C, its derivatives,
and 35S-radiolabeled ubiquitin, clarified
supernatants were passed over a MonoQ HR5/10 ion-exchange column
equilibrated with 50 mM Tris-HCl (pH 7.5)-1 mM EDTA-1 mM DTT. The
flowthrough was concentrated to 2 ml by Centricon filtration and then
run over a MonoS HR5/10 ion-exchange column (Pharmacia) equilibrated
with 50 mM HEPES (pH 7.5)-1 mM EDTA-1 mM DTT. The flowthrough was
again collected and concentrated to 500 µl and then passed over a
Superdex 75 HR10/30 size exclusion column equilibrated with 50 mM HEPES
(pH 7.5)-150 mM NaCl-1 mM EDTA-1 mM DTT. Peak fractions were
collected, pooled, and concentrated to 500 µl. Glycerol was added to
a final concentration of 5%, and the protein samples were stored at
80°C. Each of these protocols resulted in essentially pure protein
with typical yields of 0.25 to 0.5 mg/100 ml of culture. Purified
poly-His-tagged E1 from S. cerevisiae (Uba1-6His) was a
gift from S. Sadis and D. Finley (Harvard Medical School).
E2-ubiquitin thiol ester formation.
Thiol ester reactions
were performed in 0.5 ml of buffer A (10 mM HEPES, 40 mM NaCl, 5 mM
MgCl2, 5 mM ATP, 50 µg of bovine serum albumin
per ml [final pH 7.5]) supplemented with the protease inhibitors
antipain, aprotinin, chymostatin, leupeptin, and pepstatin A (each at
20 µg/ml), phenylmethylsulfonyl fluoride (180 µg/ml), and an ATP
regeneration system (5 µg of creatine kinase per ml, 0.6 U of
inorganic pyrophosphatase per ml, 3.3 mg of phosphocreatine per ml).
Also present in each reaction mixture were E2 (100 nM) and
[35S]ubiquitin (100 nM with a specific activity
of 1.5 × 105 cpm/µg). The reaction was
initiated by the addition of ubiquitin-activating enzyme (Uba1-6His at
25 nM), followed by a 5-min incubation at 30°C prior to subsequent
analysis. With these reaction conditions, E2-ubiquitin thiol ester
yields varied linearly with respect to the E2 concentrations of the
positive controls rad6
C and ubc1
C.
E2 structural alignment. Three-dimensional structures of S. cerevisiae UBC1 (unpublished data), RAD6 (UBC2; 58), UBC4, and UBC7 (4, 5) and Homo sapiens UBC9 (54) were aligned by using the Superimpose function contained within the Viewer module of Insight II, version 95.0 (Molecular Simulations Inc.). Alignments were performed by using nine structurally conserved amino acid positions distributed throughout the length of the polypeptide (positions 17, 34, 49, 66, 77, 86, 96, 110, and 135 according to the numbering of S. cerevisiae UBC4). The root mean square deviation for these four superimposed structures at the nine positions indicated equaled 0.83 Å. The resulting alignment served as the guide for the computer-aided alignment of the remaining E2 catalytic domains shown in Fig. 3 (1, 10, 11, 14, 20, 21, 30, 45-47, 52, 57). The evolutionary analysis shown in Fig. 2 was generated by the Clustal method (contained in MegAlign-DNA Star) using the multiple-protein sequence alignment described above.
Amino acid substitutions used for E2 surface maps (see Fig.
4).
For rad6
C, UBC4, and ubc1
C, amino acid substitutions
with and without phenotypic effects were taken from Table 2.
Characterized substitutions from other sources were as follows (square
brackets denote multiple substitutions) for RAD6: no effect on RAD6 DNA repair function, [K17A, E18A, D19A], [E58A, D60A, E61A, E62A], [K132A, D132A, K134A], and [K139A, R140A, K142A, E143A]; negative effect on RAD6 DNA repair function, [R6A, R7A, R8A], [K71A, E75A], and [E86A, D90A] (33). Those for CDC34 were as follows:
no effect on CDC34 function, [R4A, K5A], [R14A, R17A, E18A],
[D21A, K23A, K24A], [E32A, E34A, D35A, D36A], [E51A, D52A],
[K61A, R65A], [E68A, D69A], R78A, E122A, [E133A, D134A], [D144A,
D148A], [R150A, K151A, E154A], [K157A, R159A, K161A], [E163A,
E165A, R166A], [K168A, D170A], [R14A, R17A, E18A, D21A, K23A,
K24], and [D144A, D148A, R150A, K151A, E154A]; negative effect on
CDC34 function, [R90A, D91A, R93A], [E109A, D111A, E113A]
(36), [S97A or D], [S139A or D], and [G103 to T114
deleted] (31).
| |
RESULTS |
|---|
|
|
|---|
We approached the problem of E2 specificity with the simple assumption that the unique determinants of specificity for each E2 catalytic domain could be identified by searching for amino acids whose transposition from one E2 to another resulted in a corresponding transposition of function. Such an approach has previously been used to make a single amino acid substitution in NEDD8, making it a substrate for the ubiquitin pathway (56). The ubiquitin-conjugating enzymes UBC4 and RAD6 (UBC2) from S. cerevisiae were employed, as each carries out a distinct, nonoverlapping function and their respective biological properties can be easily measured by determining cell viability in simple plating experiments.
Initially, comparisons of the sequence similarities and differences both within and among the six members of the RAD6 and UBC4 families from S. cerevisiae, Schizosaccharomyces pombe, Drosophila melanogaster, Caenorhabditis elegans, Arabidopsis thaliana, and H. sapiens were carried out (6, 9, 24, 25, 28, 40, 41, 42, 45, 53, 55, 59). From these comparisons, we identified 21 positions that displayed strong conservation within each family but differed between families. These positions were distributed more or less uniformly throughout the E2 polypeptide, and notably, only one of these positions was not found on the protein surface (UBC4 A147, RAD6 W149).
Using this information, we attempted to convert the DNA repair function
of S. cerevisiae RAD6 (14) to the growth and
stress resistance functions of S. cerevisiae UBC4
(45) by replacing the amino acids at these 21 positions in
RAD6, either singly or in combination, with their UBC4 counterparts
(Table 1, plasmids 4 to 16). For these experiments, a derivative of
RAD6 lacking its C-terminal polyaspartate tail (rad6
C) was used
because of both the absence of the tail in other members of the RAD6
family and the fact that the tail is not essential for its DNA repair function in S. cerevisiae (34).
Contrary to our initial expectation, substitutions at 18 of these 21 positions displayed no transposition of the UBC4 growth or stress
resistance functions to rad6
C. Furthermore, these 18 substitutions
had no adverse effect on the DNA repair function of rad6
C, even when
present together in the various combinations listed in Table 1
(plasmids 4, 7, 10, 11, and 14 to 16). Thus, none of these 18 positions
plays a significant role in determining the unique characteristics of
RAD6 or UBC4.
On the other hand, two substitutions in rad6
C resulted in the
elimination of (S120D) or a strong reduction in (N123V) the DNA repair
activity of RAD6 without affecting the efficiency of E2-ubiquitin thiol
ester formation (Table 2, rows 8, 9, and 13). Neither of these
substitutions imparted any UBC4 character to rad6
C. Conversely, the
transposition of their RAD6 counterparts into UBC4 had little, if any,
effect on UBC4 function and failed to produce any degree of RAD6
function (Table 2, row 17). Thus, positions 120 and 123 are necessary,
if not sufficient, determinants of RAD6 function whereas their UBC4
counterparts (positions 118 and 121) are not essential to the UBC4
functions tested.
The DNA repair function of RAD6 has also been previously shown to be dependent upon at least one of three arginines (residues R6, R7, and R8) at its amino terminus (33). It was expected that by replacing the amino-terminal residues of RAD6 with those of UBC4 (plasmid 19), the DNA repair function of RAD6 would be lost, as UBC4 has only one arginine residue (R6) in this region, corresponding to position R8 in RAD6. Contrary to this expectation, minimal loss of DNA repair function was observed (Table 2, row 19), indicating that of the three amino-terminal arginine residues in RAD6, R8 plays the pivotal role in its DNA repair function. We confirmed this by replacing R8 in RAD6 with Q (the residue found at the analogous position in UBC9), which resulted in complete loss of the DNA repair function (Table 2, row 17).
The most striking observation that emerged from this mutational
analysis was that the single transposition of F63 from UBC4 to the N65
position of rad6
C resulted in a functionally hybrid E2 that had
acquired the growth and stress properties of UBC4 with minimal loss of
its original DNA repair properties (Table 2, row 5). The N65F
derivative of rad6
C also acquired UBC4's ability to degrade a
noncleaved ubiquitin-
-galactosidase fusion (data not shown), as
originally reported by Johnson et al. (17, 18). A similar
but weaker effect was observed when N80 of UBC4 was transposed to the
Y82 position of rad6
C, which also augmented the UBC4 character
of rad6
C when combined with the N65F transposition with
minimal loss of its DNA repair function (Table 2, rows 6 and 12).
Notably, the reciprocal F63N and N80Y transpositions into UBC4 had
little, if any, effect on UBC4 function (Table 2, row 17) and these
transpositions did not impart any RAD6 characteristics to UBC4.
Two conclusions can be drawn from this analysis. (i) The functional determinants of RAD6 and UBC4 are not spatially equivalent but map to different regions on the E2 surface. This accounts for the ability of one E2 to acquire the properties of the other while retaining its own characteristics. (ii) RAD6 has more functionally relevant surface properties in common with UBC4 than would be predicted on the basis of function or sequence comparisons.
A pluripotent E2.
Previous studies have shown that appending
the CDC34 tail to the catalytic domain of RAD6 (but not UBC4) creates
an E2 chimera capable of fully substituting for the cell cycle function
of CDC34 without loss of RAD6 DNA repair activity (26,
50). Given the observations cited above, it seemed reasonable to
expect that by appending the CDC34 tail to the bifunctional
rad6
C F65 derivative, a pluripotent E2 could be created that
incorporates the UBC4, RAD6, and CDC34 activities in a single
polypeptide. Contrary to our expectation, we observed that a chimeric
E2 consisting of rad6
C F65 and the CDC34 tail could rescue the
cdc34
-null strain and the UV sensitivity of the
rad6
-null strain (Fig. 1)
but severely exacerbated the growth phenotype of the
ubc4
ubc5
-null strain (data not shown).
Thus, the CDC34 tail appears to interfere with an essential function,
likely that of the remaining UBC4 family member, UBC1. This observation
raises the possibility that one role of an E2s carboxy-terminal
extension is to isolate a particular function to that E2.
|
170 catalytic domain
can substitute for CDC34 in the absence of the CDC34 tail (26,
50); therefore, it was a surprise to find that the rad6
C F65
catalytic domain was able to restore significant partial function to
the CDC34-null strain (Fig. 1). In contrast, the rad6
C [F65 N82]
derivative is inactive with respect to CDC34 function (Fig. 1). The
CDC34 character of rad6
C F65, relative to rad6
C and rad6
C
[F65, N82], can be partially explained by the fact that F65 and Y82
of rad6
C F65 are analogs of F72 and Y89 in CDC34. The failure of
rad6
C [F65, N82] and the RAD6 catalytic domain, [N65, Y82], to
function as CDC34 establishes these two residues as critical
determinants of CDC34 function within the context of rad6
C. What
makes this result particularly striking, however, is that a single
amino acid replacement not only bypasses the CDC34 tail as an
obligatory cell cycle determinant but also blends the functional
properties of the three E2s within a single catalytic domain.
Evolutionary relationships. The ability of the RAD6 catalytic domain to accommodate the functions of UBC4 and CDC34 in addition to its own suggested the possibility that these three E2s diverged from a common RAD6-like E2 progenitor that embodied the functions related to stress response, cell cycle, and DNA repair. In light of the fundamental importance of these processes to cell viability, such a divergence may have been among the first in E2 evolution.
These contentions are supported by the S. cerevisiae E2 phylogenetic analysis shown in Fig. 2. Typically, the precision of these sorts of analyses depends on the accuracy of the multiple-peptide sequence alignment from which they are derived. In turn, the precision of this alignment is strongly influenced by arbitrarily established penalties associated with the positions of gaps and insertions within a given sequence. To minimize alignment uncertainty, we first produced an alignment of five structurally determined E2s based on their structural superimposition (see Materials and Methods). This alignment served as a reliable basis for the fitting of the remaining E2s from S. cerevisiae (Fig. 3). The phylogenetic relationships that arise from this analysis indicate that E2s diverged from a common ancestor at a similar time into three branches, leading to separate lineages for modern RAD6, UBC4, and CDC34.
|
|
Mapping of the determinants of specificity.
A picture of the
structural relationships among RAD6, UBC4, and CDC34 emerges when the
mutational analyses derived from this work and elsewhere (see Materials
and Methods) are combined with protein sequence comparisons and viewed
in three dimensions. In Fig. 4, a
structurally based schematic of the RAD6 catalytic domain is used as a
common template to highlight three different surface attributes of the
three E2s. Gray areas highlight surface features that are common to all
previously identified E2s and include the solvent-exposed backbone and
residue side chains that are identical from protein to protein. These
regions are expected to include sites of interactions for ubiquitin and
E1 that are required for the universally shared process of E2-ubiquitin
thiol ester formation. Ubc9 and Ubc12 were naturally excluded from this
analysis because of their involvement in non-ubiquitin conjugation
processes involving the ubiquitin homologues Smt3 (Sumo-1) and Rub1,
respectively (19, 27). Open symbols correspond to the
positions of individual side chains that are presumed to be
functionally inessential based on their lack of conservation within a
given E2 family (circles) or directly demonstrated to be inessential by
site-specific mutagenesis (squares). Closed symbols denote side chains
that have been shown to play a role in functional properties that are
unique to a given E2 without affecting E2-ubiquitin thiol ester
formation (squares) or side chains that are candidates for unique
functional determinants based on their conservation within a given E2
family, coupled with their lack of conservation between E2 families,
and which could not be excluded on the basis of existing mutational
data (circles).
|
C in the case
of UBC4; tx61 [37] and rad6
C F65 in the case of CDC34). Thus, many of the conserved residues that are less important to
the specific properties of UBC4 or CDC34 can be filtered out by
selecting only surface residues that are conserved within each of their
complementation groups.
A three-dimensional representation of these data is presented in Fig.
5. As in Fig. 4, gray residues highlight
regions that are common to all E2s. Colored residues correspond to
determinants that are specific to the UBC4 function (green), the CDC34
function (magenta), or the RAD6 function (blue). In each E2 example,
the darker color highlights residues that have been established as determinants by mutational analyses. The lighter color corresponds to
determinants that have been implicated both by their conservation within the UBC4 or CDC34 complementation groups, coupled with their
lack of conservation in functionally unrelated E2s. What emerges from
Fig. 4 and 5 is a general relationship between the surface structure of
three E2 catalytic domains and the functional properties associated
with each. The portion of the catalytic domain that appears to be most
important to E2 function exists largely as a continuous surface that
surrounds the active site. This surface is actually a patchwork that is
formed from the intimate association of patches involved in the generic
functions of all E2s, such as ubiquitin and E1 interactions, and
patches associated with the unique functional properties of each E2. In
some cases, the boundaries that demarcate patches are similar between
E2s. In other cases, boundaries vary between E2s. The observation that RAD6 has preserved the determinants of other E2s in addition to its own
underscores the structural interpretation that not all of these
determinants are spatially coincident.
|
| |
DISCUSSION |
|---|
|
|
|---|
Two opposing evolutionary forces appear to have shaped the forms of contemporary E2s. On the one hand, the evolutionary inertia that preserved the key catalytic elements common to all E2s resisted changes to their structures. On the other hand, the tendency toward structural variation provided a source for the diversity of functions observed among E2s today.
The generation of E2 diversity appears to have occurred in two possible ways: (i) changes in the distribution of amino acids on a common E2 frame through amino acid substitutions and (ii) the introduction of novel peptide elements through insertions and extensions.
We propose that E2s evolved from an ancestral E2 capable of carrying
out multiple E2 functions. Phylogenetic evidence and the pluripotent
nature of rad6
C F65 suggest that RAD6 most closely resembles this
ancestral E2 and that it consisted solely of the conserved E2 catalytic
domain. Subsequent gene duplication, coupled with changes in the
distribution of amino acids within the conserved catalytic domain, may
have led to E2 diversity and functional specialization. In some
instances, such changes appear to have been coupled with insertions and
extensions, such as in the case of CDC34. Curiously, these additional
peptide elements are not required for the cell cycle function of CDC34
based on the pluripotent nature of rad6
C F65. Similarly, other work
has shown that deletion of CDC34's catalytic domain insertion, in
combination with proper amino acid substitutions, generates a fully
functional derivative of CDC34 (31). Furthermore, these
changes convert these positions to the residues found in RAD6, possibly
accounting for the ability of rad6
C F65 to carry out this cell cycle
function in the absence of the catalytic domain insertion.
These examples highlight the fact that, even though insertions and extensions may have been acquired to define functional specificity, these functions remain an inherent part of the catalytic domain. These insertions and extensions appear to be dispensable with respect to E2 function and were likely acquired at some point after E2 functions had been established within the catalytic domain.
This interpretation is supported by sequence comparisons and phylogenetic analysis. With respect to insertions, this analysis suggests that the short and variable lengths of E2 insertions did not appear abruptly, carrying with them new functional attributes, but rather developed incrementally with time. Interestingly, the phylogenetic analysis presented in Fig. 2 indicates that most of the loops in present-day E2s arose fairly infrequently and independently from one another after the divergence of UBC4 and CDC34 from RAD6. The notable exceptions to this conclusion are the loops of UBC7 and CDC34, which were clearly acquired from a common ancestor. The observation that these loops are not absolutely required for the in vivo activity of these E2s is consistent with this phylogenetic interpretation (31). The infrequent and independent appearance of loops at only two positions within the catalytic domain attests to the tight evolutionary constraint placed on its modification.
Phylogenetic evidence also suggests that while extensions play a role in E2 specificity, they too were acquired relatively late in the chronology of E2, after many of their functions had been established (Fig. 2). The tails of CDC34, RAD6, and UBC1, for example, were all acquired following the divergences that led to their final forms. This conclusion is also supported by E2 comparisons across species. The tail of CDC34 shares only 9% identity with the tail of its human counterpart, tx61 (37), and the two are therefore unlikely to have the same evolutionary origin. The fact that tx61 can substitute for CDC34 in vivo argues against the notion that the tail plays a central role in substrate specificity. Similarly, the polyaspartate tail of RAD6 is not found on any of the other RAD6 homologues identified from other organisms and is not required for the DNA repair function of RAD6 (34). Finally, the tail of UBC1 exhibits only 13% identity with its bovine homologue, E2-25K, indicating that these tails are likely of independent origin. As in the case of RAD6, the tail of UBC1 is not required for its stress response activity (Table 2, row 2). The phylogenetic evidence therefore suggests that several essential E2 functions were fixed in a primordial E2 prior to the acquisition of inserts and extensions.
E2 structure and function.
From the standpoint of structure,
the most striking feature of the E2 surface is the distribution of
residues that are conserved among all E2s, relative to residues
that probably contributed to the functional divergence of UBC4, RAD6,
and CDC34 (Fig. 5). Both classes of residues are found as a
largely contiguous patchwork that surrounds the active-site
cysteine. When combined, the determinants of UBC4, RAD6, and CDC34 form
two clusters that are separated from one another by a conserved
partition (Fig. 6). Residues that are
important to the functions of each of these E2s can be found in both
clusters (Fig. 5).
|
C to E3s that
are specific to either UBC4 (such as the HECT domain protein UFD4
[17, 23] or the RING domain protein APC11
[29]) or CDC34 (such as the RING domain protein HRT1
[22, 44, 51]).
While this position plays a role as a general site for E3 binding, it
appears that other elements on the functional E2 face are required to
define the specificity of the interaction of any given E2-E3 pair. For
example, a substitution at position 65 of RAD6 has little effect on its
ability to participate in the DNA repair pathway (Table 2, row 5).
Thus, position 65 may play a role in RAD6-E3 interactions, such as with
RING domain protein RAD18, but other elements must define the
specificity of these interactions. Such elements might include
positions 8, 120, and 123, given that amino acid substitutions at these
positions dramatically affect its DNA repair function.
Similarly, replacement of the phenylalanine at the analogous position
in UBC4 (F63N) has virtually no effect on UBC4 function (Table 2, row
18). In this case, the interaction of UBC4 with an E3 probably places a
greater emphasis on residues that lie adjacent to or near F63.
Finally, while the F65 substitution appears to adapt the RAD6 catalytic
domain to multiple E3s, the efficacy of this adaptation in terms of
gain of function is dependent on other positions within the catalytic
domain, in particular, on position 82 of rad6
C. In the pluripotent
rad6
C F65 derivative, position 82 carries a Y residue. In this
configuration, all three E2 functions are carried out by a single E2,
albeit to various degrees (Table 2; Fig. 1). When the Y82N substitution
is made, however, the UBC4 function is enhanced while the RAD6 function
is again partially affected and the CDC34 function is completely
eliminated. This observation highlights the need not only for the
correct residue at the general E3 binding site but the need for
residues outside of this site.
Throughout most of its evolution, RAD6 has apparently preserved the
capacity to interact with several structurally unrelated E3s. It is
unlikely that these different E3-dependent mechanisms of target
selection were all rooted by a common evolutionary origin. Rather, the
dissimilarity among these E3s suggests that different proteins
independently evolved an affinity for the catalytic face of the E2. The
simplest conclusion that can be drawn from these findings is that the
mechanistic variations that are employed in target selection owe their
existence to the multivalency of RAD6's antecedent.
| |
ACKNOWLEDGMENTS |
|---|
This work was made possible by grants from the Medical Research Council of Canada (MRC), the National Cancer Institute of Canada, and the Alberta Heritage Foundation for Medical Research (AHFMR). M.J.E. is an MRC Scientist and an AHFMR Senior Scholar.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Biochemistry, University of Alberta, Edmonton, Alberta T6G 2H7, Canada. Phone: (780) 492-5839. Fax: (780) 492-0886. E-mail: mike.ellison{at}ualberta.ca.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Broomfield, S.,
B. L. Chow, and W. Xiao.
1998.
MMS2 encoding a ubiquitin-conjugating-enzyme-like protein is a member of the yeast error-free postreplication repair pathway.
Proc. Natl. Acad. Sci. USA
95:5678-5683 |
| 2. |
Chen, P.,
P. Johnson,
T. Sommer,
S. Jentsch, and M. Hochstrasser.
1993.
Multiple ubiquitin-conjugating enzymes participate in the in vivo degradation of the yeast MAT 2 repressor.
Cell
74:357-369[CrossRef][Medline].
|
| 3. |
Cook, W. J.,
L. C. Jeffery,
M. L. Sullivan, and R. D. Vierstra.
1992.
Three-dimensional structure of a ubiquitin-conjugating enzyme E2.
J. Biol. Chem.
267:15116-15121 |
| 4. | Cook, W. J., L. C. Jeffery, Y. Xu, and V. Chau. 1993. Tertiary structures of class I ubiquitin-conjugating enzymes are highly conserved: crystal structure of yeast UBC4. Biochemistry 32:13809-13817[CrossRef][Medline]. |
| 5. | Cook, W. J., P. D. Martin, B. F. Edwards, R. K. Yamazaki, and V. Chau. 1997. Crystal structure of a class I ubiquitin conjugating enzyme (UBC7) from Saccharomyces cerevisiae at 2.9 angstroms resolution. Biochemistry 36:1621-1627[CrossRef][Medline]. |
| 6. | Damagnez, V., M. Rolfe, and G Cottarel. 1995. Schizosaccharomyces pombe and Candida albicans cDNA homologues of the Saccharomyces cerevisiae UBC4 gene. Gene 155:137-138[CrossRef][Medline]. |
| 7. | Deshaies, R. J. 1999. SCF and Cullin/RING H2-based ubiquitin ligases. Annu. Rev. Cell Dev. Biol. 15:435-467[CrossRef][Medline]. |
| 8. |
Ellison, M. J., and M. Hochstrasser.
1991.
Epitope tagged ubiquitin. A new probe for analyzing ubiquitin function.
J. Biol. Chem.
266:21150-21157 |
| 9. | Girod, P. A., T. B. Carpenter, S. van Nocker, M. L. Sullivan, and R. D. Vierstra. 1993. Homologs of the essential ubiquitin conjugating enzymes UBC1, 4, and 5 in yeast are encoded by a multigene family in Arabidopsis thaliana. Plant J. 3:545-552[CrossRef][Medline]. |
| 10. |
Goebl, M. G.,
J. Yochem,
S. Jentsch,
J. P. McGrath,
A. Varshavsky, and B. Byers.
1988.
The yeast cell cycle gene CDC34 encodes a ubiquitin-conjugating enzyme.
Science
241:1331-1335 |
| 11. | Goffeau, A., B. G. Barrell, H. Bussey, R. W. Davis, B. Dujon, H. Feldmann, F. Galibert, J. D. Hoheisel, C. Jacq, M. Johnston, E. J. Louis, H. W. Mewes, Y. Murakami, P. Philippsen, H. Tettelin, and S. G. Oliver. 1996. Life with 6000 genes. Science 274:563-567. |
| 12. |
Hodgins, R.,
C. Gwozd,
T. Arnason,
M. Cummings, and E. M. Ellison.
1996.
The tail of ubiquitin-conjugating enzyme redirects multi-ubiquitin chain synthesis from the lysine 48-linked configuration to a novel nonlysine-linked form.
J. Biol. Chem.
271:28766-28771 |
| 13. |
Huang, L.,
E. Kinnucan,
G. Wang,
S. Beaudenon,
P. M. Howley,
J. M. Huibregtse, and N. P. Pavletich.
1999.
Structure of an E6AP-UbcH7 complex: insights into ubiquitination by the E2-E3 enzyme cascade.
Science
286:1321-1326 |
| 14. | Jentsch, S., J. P. McGrath, and A. Varshavsky. 1987. The yeast DNA repair gene RAD6 encodes a ubiquitin-conjugating enzyme. Nature 329:131-134[CrossRef][Medline]. |
| 15. | Jentsch, S. 1992. The ubiquitin-conjugation system. Annu. Rev. Genet. 26:179-207[CrossRef][Medline]. |
| 16. | Jiang, F., and R. Basavappa. 1999. Crystal structure of the cyclin-specific ubiquitin-conjugating enzyme from clam, E2-C, at 2.0 A resolution. Biochemistry 38:6471-6478[CrossRef][Medline]. |
| 17. | Johnson, E. S., B. Bartel, W. Seufert, and A. Varshavsky. 1992. Ubiquitin as a degradation signal. EMBO J. 11:497-505[Medline]. |
| 18. |
Johnson, E. S.,
P. C. Ma,
I. M. Ota, and A. Varshavsky.
1995.
A proteolytic pathway that recognizes ubiquitin as a degradation signal.
J. Biol. Chem.
270:17442-17456 |
| 19. |
Johnson, E. S., and G. Blobel.
1997.
Ubc9p is the conjugating enzyme for the ubiquitin-like protein Smt3p.
J. Biol. Chem.
272:26799-26802 |
| 20. | Jungmann, J., H. A. Reins, C. Schobert, and S. Jentsch. 1993. Resistance to cadmium mediated by ubiquitin-dependent proteolysis. Nature 361:369-371[CrossRef][Medline]. |
| 21. |
Kaiser, P.,
W. Seufert,
L. Hofferer,
B. Kofler,
C. Sachsenmaier,
H. Herzog,
S. Jentsch,
M. Schweiger, and R. Schneider.
1994.
A human ubiquitin-conjugating enzyme homologous to yeast UBC8.
J. Biol. Chem.
269:8797-8802 |
| 22. |
Kamura, T.,
D. M. Koepp,
M. N. Conrad,
D. Skowyra,
R. J. Moreland,
O. Iliopoulos,
W. S. Lane,
W. G. Kaelin, Jr.,
S. J. Elledge,
R. C. Conaway,
J. W. Harper, and J. W. Conaway.
1999.
RBX1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase.
Science
284:657-661 |
| 23. | Koegl, M., T. Hoppe, S. Schlenker, H. D. Ulrich, T. U. Mayer, and S. Jentsch. 1999. A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell 96:635-644[CrossRef][Medline]. |
| 24. |
Koken, M.,
P. Reynolds,
D. Bootsma,
J. Hoeijmakers,
S. Prakash, and L. Prakash.
1991.
DHR6, a Drosophila homolog of the yeast DNA-repair gene RAD6.
Proc. Natl. Acad. Sci. USA
88:3832-3836 |
| 25. |
Koken, M. H.,
P. Reynolds,
I. Jaspers-Dekker,
L. Prakash,
S. Prakash,
D. Bootsma, and J. H. Hoeijmakers.
1991.
Structural and functional conservation of two human homologs of the yeast DNA repair gene RAD6.
Proc. Natl. Acad. Sci. USA
88:8865-8869 |
| 26. | Kolman, C. J., J. Toth, and D. K. Gonda. 1992. Identification of a portable determinant of cell cycle function within the carboxy-terminal domain of the yeast CDC34 (UBC3) ubiquitin (E2) conjugating enzyme. EMBO J. 11:3081-3090[Medline]. |
| 27. |
Lammer, D.,
N. Mathias,
J. M. Laplaza,
W. Jiang,
Y. Liu,
J. Callis,
M. Goebl, and M. Estelle.
1998.
Modification of yeast CDC53p by the ubiquitin-related protein RUB1p affects function of the SCF-CDC4 complex.
Genes Dev.
12:914-926 |
| 28. | Leggett, D. S., D. Jones, and E. P. Candido. 1995. Caenorhabditis elegans UBC-1, a ubiquitin-conjugating enzyme homologous to yeast RAD6/UBC2, contains a novel carboxy-terminal extension that is conserved in nematodes. DNA Cell Biol. 14:883-891[Medline]. |
| 29. | Leverson, J. D., C. Joazeiro, A. M. Page, H.-K. Huang, P. Hieter, and T. Hunter. The Apc11 RING-H2 finger mediates E2-dependent ubiquitination. Mol. Biol. Cell 11:2315-2325. |
| 30. | Liakopoulos, D., G. Doenges, K. Matuschewski, and S. Jentsch. 1998. A novel protein modification pathway related to the ubiquitin system. EMBO J. 17:2208-2214[CrossRef][Medline]. |
| 31. | Liu, Y., N. Mathias, N. Steussy, and M. G. Goebl. 1995. Intragenic suppression among CDC34 (UBC3) mutations defines a class of ubiquitin-conjugating catalytic domains. Mol. Cell. Biol. 15:5635-5644[Abstract]. |
| 32. |
Mathias, N.,
N. C. Steussy, and M. G. Goebl.
1998.
An essential domain within CDC34p is required for binding to a complex containing CDC34p and CDC53p in Saccharomyces cerevisiae.
J. Biol. Chem.
273:4040-4045 |
| 33. |
McDonough, M.,
P. Sangan, and D. K. Gonda.
1995.
Characterization of novel yeast RAD6 (UBC2) ubiquitin-conjugating enzyme mutants constructed by charge-to-alanine scanning mutagenesis.
J. Bacteriol.
177:580-585 |
| 34. |
Morrison, A.,
E. J. Miller, and L. Prakash.
1988.
Domain structure and functional analysis of the carboxyl-terminal polyacidic sequence of the RAD6 protein of Saccharomyces cerevisiae.
Mol. Cell. Biol.
8:1179-1185 |
| 35. | Pickart, C. M. 1998. Polyubiquitin chains, p. 19-63. In J.-M. Peters, J. R. Harris, and D. Finley (ed.), Ubiquitin and the biology of the cell. Plenum Press, Inc., New York, N.Y. |
| 36. | Pitluk, Z. W., M. McDonough, P. Sangan, and D. K. Gonda. 1995. Novel CDC34 (UBC3) ubiquitin-conjugating enzyme mutants obtained by charge-to-alanine scanning mutagenesis. Mol. Cell. Biol. 15:1210-1219[Abstract]. |
| 37. |
Plon, S. E.,
K. A. Leppig,
H. N. Do, and M. Groudine.
1993.
Cloning of the human homolog of the CDC34 cell cycle gene by complementation in yeast.
Proc. Natl. Acad. Sci. USA
90:10484-10488 |
| 38. | Ptak, C., J. A. Prendergast, R. Hodgins, C. M. Kay, V. Chau, and M. J. Ellison. 1994. Functional and physical characterization of the cell cycle ubiquitin-conjugating enzyme CDC34 (UBC3): identification of a functional determinant within the tail that facilitates CDC34 self-association. J. Biol. Chem. 42:26539-26545. |
| 39. | Rechsteiner, M. 1998. The 26S proteosome, p. 147-189. In J.-M. Peters, J. R. Harris, and D. Finley (ed.), Ubiquitin and the biology of the cell. Plenum Press, Inc., New York, N.Y. |
| 40. |
Reynolds, P.,
S. Weber, and L. Prakash.
1985.
RAD6 gene of Saccharomyces cerevisiae encodes a protein containing a tract of 13 consecutive aspartates.
Proc. Natl. Acad. Sci. USA
82:168-172 |
| 41. | Reynolds, P., M. H. Koken, J. H. Hoeijmakers, S. Prakash, and L. Prakash. 1990. The rhp6+ gene of Schizosaccharomyces pombe: a structural and functional homolog of the RAD6 gene from the distantly related yeast Saccharomyces cerevisiae. EMBO J. 9:1423-1430[Medline]. |
| 42. |
Scheffner, M.,
J. M. Huibregtse, and P. M. Howley.
1993.
Identification of a human ubiquitin-conjugating enzyme that mediates the E6-AP dependent ubiquitination of p53.
Proc. Natl. Acad. Sci. USA
91:8797-8801 |
| 43. | Scheffner, M., S. Smith, and S. Jentsch. 1998. The ubiquitin-conjugation system, p. 65-98. In J.-M. Peters, J. R. Harris, and D. Finley (ed.), Ubiquitin and the biology of the cell. Plenum Press, Inc., New York, N.Y. |
| 44. |
Seol, J. H.,
R. M. Feldman,
W. Zachariae,
A. Shevchenko,
C. C. Correll,
S. Lyapina,
Y. Chi,
M. Galova,
J. Claypool,
S. Sandmeyer,
K. Nasmyth, and R. J. Deshaies.
1999.
Cdc53/cullin and the essential hrt1 RING-H2 subunit of SCF define a ubiquitin ligase module that activates the E2 enzyme cdc34.
Genes Dev.
13:1614-1626 |
| 45. | Seufert, W., and S. Jentsch. 1990. Ubiquitin-conjugating enzymes UBC4 and UBC5 mediate selective degradation of short-lived and abnormal proteins. EMBO J. 9:543-550[Medline]. |
| 46. | Seufert, W., J. P. McGrath, and S. Jentsch. 1990. UBC1 encodes a novel member of an essential subfamily of yeast ubiquitin-conjugating enzymes involved in protein degradation. EMBO J. 9:4535-4541[Medline]. |
| 47. | Seufert, W., B. Futcher, and S. Jentsch. 1995. Role of a ubiquitin-conjugating enzyme in degradation of S- and M-phase cyclins. Science 373:78-81. |
| 48. | Sherman, F., G. R. Fink, and J. B. Hicks. 1986. Methods in yeast genetics. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 49. |
Sikorski, R. S., and P. Hieter.
1989.
A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae.
Genetics
122:19-27 |
| 50. | Silver, E. T., T. J. Gwozd, C. Ptak, M. Goebl, and M. J. Ellison. 1992. A chimeric ubiquitin conjugating enzyme that combines the cell cycle properties of CDC34 (UBC3) and the DNA repair properties of RAD6 (UBC2): implications for the structure, function, and evolution of the E2s. EMBO J. 11:3091-3098[Medline]. |
| 51. |
Skowyra, D.,
D. M. Koepp,
T. Kamura,
M. N. Conrad,
R. C. Conaway,
J. W. Conaway,
S. J. Elledge, and J. W. Harper.
1999.
Reconstitution of G1 cyclin ubiquitination with complexes containing SCFGRR1 and RBX1.
Science
284:662-665 |
| 52. | Sommer, T., and S. Jentsch. 1993. A protein translocation defect linked to ubiquitin conjugation at the endoplasmic reticulum. Nature 365:176-179[CrossRef][Medline]. |
| 53. |
Sullivan, M. L., and R. D. Vierstra.
1991.
Cloning of a 16-kDa ubiquitin carrier protein from wheat and Arabidopsis thaliana. Identification of functional domains by in vitro mutagenesis.
J. Biol. Chem.
266:23878-23885 |
| 54. |
Tong, H.,
G. Hateboer,
A. Perrakis,
R. Bernards, and T. K. Sixma.
1997.
Crystal structure of murine/human Ubc9 provides insight into the variability of the ubiquitin conjugating system.
J. Biol. Chem.
272:21381-21387 |
| 55. | Treier, M., W. Seufert, and S. Jentsch. 1992. Drosophila UbcD1 encodes a highly conserved ubiquitin-conjugating enzyme involved in selective protein degradation. EMBO J. 11:367-372[Medline]. |
| 56. |
Whitby, F. G.,
G. Xia,
C. M. Pickart, and C. P. Hill.
1998.
Crystal structure of the human ubiquitin-like protein NEDD8 and interactions with ubiquitin pathway enzymes.
J. Biol. Chem.
273:34983-34991 |
| 57. | Wiebel, F. F., and W.-H. Kunau. 1992. The Pas2 protein essential for peroxisome biogenesis is related to ubiquitin-conjugating enzymes. Nature 359:73-76[CrossRef][Medline]. |
| 58. |
Worthylake, D. K.,
S. Prakash, and C. P. Hill.
1998.
Crystal structure of the Saccharomyces cerevisiae ubiquitin-conjugating enzyme Rad6 at 2.6 A resolution.
J. Biol. Chem.
273:6271-6276 |
| 59. |
Zhen, M.,
R. Heinlein,
D. Jones,
S. Jentsch, and E. P. M. Candido.
1993.
The ubc-2 gene of Caenorhabditis elegans encodes a ubiquitin-conjugating enzyme involved in selective protein degradation.
Mol. Cell. Biol.
13:1371-1377 |
| 60. | Zheng, N., P. Wang, P. D. Jeffrey, and P. Pavletich. 2000. Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases. Cell 102:533-539[CrossRef][Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»